<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="8336">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02035904</url>
  </required_header>
  <id_info>
    <org_study_id>2011-006331-35</org_study_id>
    <nct_id>NCT02035904</nct_id>
  </id_info>
  <brief_title>Levobupivacaine Prolonged Wound Infusion for Postoperative Pain Relief After Breast Surgery</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>IRCCS Policlinico S. Matteo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IRCCS Policlinico S. Matteo</source>
  <oversight_info>
    <authority>Italy: Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to evaluate efficacy and safety of long term (14 days) wound
      infusion with levobupivacaine in patients with breast cancer undergoing mastectomy with
      immediate breast reconstruction:  this is a double blind, randomized, parallel group study.
      The study moves from the concept that nociceptive stimulus last further than 48 hours after
      surgical intervention: long term analgesia is necessary to provide a real benefit to the
      patient and provide central sensitization. Intralesional catheter is placed at the end of
      surgery. In the first 24 postoperative hours we provide continuous wound infusion with
      levobupivacaine 0,25% 5ml/h with morphine Patient Controlled Analgesia (PCA) when NRS &gt;4.
      From the second postoperative day morphine PCA is removed  and patients are randomized to
      receive levobupivacaine 0,25% or saline, released with 5 ml boluses and lock-out of 2 hours,
      with rescue analgesia with tramadol 37,5 mg + acetaminophen 325 mg oral fix combination
      (Patrol). Intralesional catheter is taken off 14 days after surgical intervention or after
      36 hours of non-use.

      Pain evaluation (NRS at rest and movement) and oral rescue doses consumption are performed;
      pain physicians also care about any catheter-related or drug-related side effect,
      registering number of total boluses. Patients are provided with a home diary for pain scores
      to be filled and brought back when surgical visit is performed. A phone interview at 1 and 3
      month is performed to investigate pain chronicization.

      Surgical evaluation is provided, also to establish any catheter-related infective or healing
      complication.

      Physiatric evaluation before the intervention and 1 and 3 months is provided to ensure
      rehabilitation process.

      A validated questionnaire (short form 36/ SF-36) must be filled by all patients, to
      understand differences in return to a normal quality of life and to social activities
      between the two groups.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>reduction in oral Tramadol-Paracetamol combination consumption from 2nd to 14th day after mastectomy</measure>
    <time_frame>from day 2 to 14</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>reduction in pain values at rest and movement in treatment group</measure>
    <time_frame>14 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of drug-related side effects</measure>
    <time_frame>up to 14 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>local anesthetic toxicity, opioid side effects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of catheter-related surgical complications</measure>
    <time_frame>up to 1 month</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>infections, healing retardation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>earlier upper limb rehabilitation</measure>
    <time_frame>up to 1 month</time_frame>
    <safety_issue>No</safety_issue>
    <description>physiatric evaluations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>earlier return to social activities and good quality of life</measure>
    <time_frame>up to 1 month</time_frame>
    <safety_issue>No</safety_issue>
    <description>validated SF-36 questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>different chronic pain incidence</measure>
    <time_frame>up to 3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>phone interview at 1 and 3 months</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Acute Pain</condition>
  <condition>Chronic Pain</condition>
  <condition>Wound Infusion</condition>
  <condition>Mastectomy</condition>
  <arm_group>
    <arm_group_label>Levobupivacaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Levobupivacaine Patient Controlled Infusion 5 ml 0,25%, lock out 2 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>patient controlled infusion 5 ml bolus, lock out 2 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levobupivacaine PCIA (Patient Controlled Intrawound Analgesia)</intervention_name>
    <description>patient controlled infusion from the 2nd day after surgery</description>
    <arm_group_label>Levobupivacaine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>saline</intervention_name>
    <description>patient controlled infusion from the 2nd day after surgery</description>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levobupivacaine continuous infusion</intervention_name>
    <description>Continuous infusion Levobupivacaine 0,25% 5ml/h for 24 hs in all patients</description>
    <arm_group_label>Levobupivacaine</arm_group_label>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>intrawound infusion catheter</intervention_name>
    <description>placed by surgeon at the end surgery in all patients</description>
    <arm_group_label>Levobupivacaine</arm_group_label>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>morphine</intervention_name>
    <description>PCA with morphine: 0,5 mg/ml bolus 1 mg lock-out 5 min max 20 mg in 4 hs - for the first 24 hs as rescue analgesia</description>
    <arm_group_label>Levobupivacaine</arm_group_label>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Patrol</intervention_name>
    <description>tramadol-paracetamol 37,5/325 mg oral fix combination-rescue analgesia from 2nd day (after morphine PCA removal)</description>
    <arm_group_label>Levobupivacaine</arm_group_label>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  F; age 18 to 70

          -  American Society of Anesthesiologists (ASA) I e II;

          -  breast cancer ( DIN 2 e 3, o LIN 2 e 3 sec. Tavassoli) scheduled for nipple-sparing
             mastectomy, simple mastectomy, skin-sparing mastectomy, skin-reducing mastectomy c,
             lymphnode biopsy and axillary dissection;

          -  immediate sub-pectoral prosthetic reconstruction;

          -  signed informed consent.

        Exclusion Criteria:

          -  preexisting pectoral, axillar, thoracic homolateral pain

          -  habitual opioid consumption;

          -  drug-alcoholics addiction ;

          -  ICU postoperative recovery;

          -  kidney failure (creatinin &gt; 2 g/dl, creatinin &lt;clearance 30 ml/h) and/or hepatic
             failure (cholinesterase &lt; 2000 UI);

          -  cardiac arrhythmias o;

          -  Epilepsy;

          -  Psychiatric, cognitive disorders, mental retardation;

          -  Coagulopathies (INR &gt; 2, activated partial thromboplastin time - aPTT&gt;44 sec);

          -  platelet count less than 100.000/mm3;

          -  BMI &gt; 30;

          -  Allergies to study drugs.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Allegri Massimo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pain Therapy Service IRCCS Policlinico S Matteo Pavia Italy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Allegri Massimo, MD</last_name>
    <phone>+390382502627</phone>
    <email>massimo.allegri@unipv.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Anesthesia - Pain Therapy Service</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Allegri Massimo, MD</last_name>
      <phone>+390382502627</phone>
      <email>massimo.allegri@unipv.it</email>
    </contact>
    <investigator>
      <last_name>Bugada Dario, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://www.simpar.eu</url>
  </link>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 13, 2014</lastchanged_date>
  <firstreceived_date>January 11, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>IRCCS Policlinico S. Matteo</investigator_affiliation>
    <investigator_full_name>Massimo Allegri</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Morphine</mesh_term>
    <mesh_term>Levobupivacaine</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
